Evidence map›Paper›PMID 29530855›Full record

Trial reportAntimicrobial agents and chemotherapy2018

Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.

M G Vossen, L Ehmann, S Pferschy, A Maier-Salamon, M Haidinger, C Weiser, J M Wenisch, K Saria, C Kajahn, S Jilch and 6 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Frontiers in pharmacology · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

M G VossenDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria matthias.vossen@meduniwien.ac.at.ORCID 0000-0002-4350-7173
L EhmannDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
S PferschyDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
A Maier-SalamonDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
M HaidingerInternistisches Zentrum Nord, Vienna, Austria.
C WeiserDepartment of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
J M WenischDepartment of Hospital Hygiene, Wilhelminenspital, Vienna, Austria.
K SariaDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
C KajahnDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
S JilchDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
R LemmererDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
M BécèdeDepartment of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
M ZeitlingerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
C KloftDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
W JägerDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
F ThalhammerDepartment of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATFreie Universität Berlin · DEUniversity of Vienna · ATWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doripenem is a broad-spectrum parenteral carbapenem with enhanced activity against

Indexed as

AdultAgedAged, 80 and overAnti-Bacterial AgentsCarbapenemsDoripenemEnterobacteriaceaeFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedPseudomonas aeruginosaRenal DialysisRenal Replacement TherapyYoung AdultAnti-Bacterial AgentsCarbapenemsDoripenemanti-infective agentshemodialysisintermittent renal replacement therapypharmacokineticspopulation pharmacokinetics

Identifiers

PMID29530855
PMCPMC5923130
OpenAlexW2802931614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.